期刊文献+

脓毒症患者中多重耐药鲍曼不动杆菌感染危险因素分析

Analysis of risk factors of multi-drug resistant acinetobacter baumannii infection in patients with sepsis
下载PDF
导出
摘要 目的 探讨综合重症监护病房(ICU)多重耐药(multi-drug resistant,MDR)鲍曼不动杆菌(Acinetobacter baumannii,Ab)感染脓毒症患者的临床特征和危险因素.方法 回顾分析2009年7月至2013年3月我院综合ICU入住脓毒症患者856例,通过比较多重耐药Ab感染脓毒症患者179例(病例组)与非多重耐药Ab感染脓毒症患者677例(对照组)的临床资料,探讨两组患者的病死率、住院费用、器官功能损害情况和死亡的危险因素.结果 多重耐药Ab感染脓毒症患者病死率、48 h病死率及住院费用较对照组高(P<0.05);多重耐药Ab感染脓毒症患者较对照组更易发生感染性休克、急性肾损伤和骨髓抑制;多重耐药Ab感染脓毒症患者如果APECHEⅡ评分>25分、24 h内出现多脏器功能障碍综合征(MODS)、感染性休克,则其死亡风险更高(P<0.05).结论 多重耐药Ab感染脓毒症患者具有病死率高、治疗费用昂贵等特征,及时发现患者的死亡危险因素并进行针对性干预极其重要. Objective To investigate the clinical characteristics and risk factors of multi-drug resistant (MDR) acinetobacter baumannii (Ab) infection in patients with sepsis in ICU.Methods Retrospectively analyzed clinical data of 856 cases of sepsis admitted in ICU of our hospital from July 2009 to March 2013,who were divided into MDR Ab related sepsis group (179 cases) and non-MDR Ab related sepsis group (control group,677 cases).Mortality rate,hospitalization expenses,organ function injury level and risk factors of death were compared between two groups.Results Mortality rate,48 hours mortality rate and hospitalization cost of MDR Ab related sepsis group were higher than those of control group (P < 0.05).Septic shock,acute kidney injury and bone marrow suppression more likely occurred in MDR Ab related sepsis group (P < 0.05).APACHE Ⅱ score > 25,septic shock and multiple organ dysfunction syndrome (MODS) within 24 h were risk factors of death in MDR Ab related sepsis group (P < 0.05).Conclusions Patients with MDR Ab related sepsis have worse prognosis and spend more in related treatment.It is important to detect risk factors of death and implement targeting treatment early.
出处 《国际医药卫生导报》 2014年第10期1354-1357,共4页 International Medicine and Health Guidance News
关键词 鲍曼不动杆菌 脓毒症 重症监护病房 危险因素 Acinetobacter baumannii Sepsis Intensive care unit Risk factors
  • 相关文献

参考文献19

  • 1Cohen J. The immunopathogenesis of sepsis [J]. Nature, 2002, 420 (6917) : 885-891.
  • 2Brun-Buisson C. The epidemiology of the systemic inflammatory response [J]. Intensive Care Med, 2000, 26 ( Suppl 1 ) : S64-74.
  • 3Lee K, Yong D, Jeong SH, et al. Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens [J]. Yonsei Med J, 2011, 52 (6) : 879-891.
  • 4Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference [J]. Crit Care Med, 2003, 31 (4) : 1250- 1256.
  • 5Marshall JC, Cook D J, Christou NV, et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome [J]. Crit Care Med, 1995, 23 (6) : 1638-1652.
  • 6Garnacho-Montero J, Garcia-Garmendia JL, Barrero- Almodovar A, et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis [J]. Crit Care Med. 2003, 31 ( 12 ) : 2742-2751.
  • 7Falagas ME, Rafailidis PI. Attributable mortality of Acinetobacter baumannii: no longer a controversial issue [J]. CritCare, 2007, 11 (3) : 134.
  • 8Falagas ME, Kasiakou SK, Rafailidis PI, et al. Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy [J]. J Antimicrob Chemother, 2006, 57 (6) : 1251-1254.
  • 9Falagas ME, Bliziotis IA, Siempos II.Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies [J]. Crit Care, 2006, 10 ( 2 ) : R48.
  • 10Dalla-Costa LM, Coelho JM, Souza HA, et al. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil [J]. J Clin Microbiol, 2003, 41 ( 7 ) : 3403-3406.

二级参考文献16

  • 1王金良.密切注视鲍曼不动杆菌的耐药发展趋势[J].中华检验医学杂志,2005,28(4):355-356. 被引量:194
  • 2杨平满,周建英.常见多重耐药菌的耐药机制及防治对策[J].中华医院感染学杂志,2006,16(12):1434-1437. 被引量:144
  • 3Federico P, Andrea M H, Kristine M H, et al. Global challenge of muhidrug-resistant Acinetobacter baumannii [J]. Antimicrob Agents Chemother, 2007, 51 (10) : 3471-3484.
  • 4Woodford N, Etlington M J, Coelho J M, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp [J]. Int J Antimicrob Agents, 2006, 27(4):351-353.
  • 5Safdar N, Christopher J C, Dennis G M. The pathogenesis of ventilator-associated pneumonia: its relevance to developing effective strategies for prevention [ J] . Respiration Care, 2005, 50 (6) : 725-741.
  • 6Zhou H, Yang Q, Yu Y S, et al. Ctonal spread of imipenem- resistant Acinetobacter baumannii among different cities of China [J]. J Clin Microbiol, 2007, 45(12) : 4054-4057.
  • 7Tasbakan M S, Pullukcu H, Ekren P K, et al. Colistin use in ventilator-associated pneumonia clue to panresistant Pseudomonas aeruginosa and Aeinetobaeter baumannii [J]. Mikrobiyol Bul, 2009, 43(1): 61-70.
  • 8Walther-Rasmussen J, Hoiby N. OXA-type carbapenemases [J]. Antimicrob Agents Chemother, 2006, 57 ( 3 ) : 373-383.
  • 9Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiotogy [J]. Clin Microbiol Infect, 2006,12(9) : 826-836.
  • 10Turton J F, Ward M E, Woodford N, et al. The role of ISAbal in expression of OXA carbapenemase genes in Acinetobacter baumannii [J ]. FEMS Microbiol Let, 2006, 258 (1): 72-77.

共引文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部